论文部分内容阅读
目的观察酒石酸美托洛尔联合阿托伐他汀治疗冠心病伴血脂异常的临床疗效。方法将76例冠心病伴血脂异常患者随机分为观察组与对照组,每组38例。两组均进行常规治疗,对照组加用美托洛尔,观察组加用美托洛尔与阿托伐他汀,疗程均为4周。结果治疗结束后,观察组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)等血脂水平均较治疗前显著下降(P<0.05),高密度脂蛋白胆固醇(HDL-C)水平较治疗前显著升高(P<0.05);观察组临床总有效率为94.74%,显著高于对照组的78.95%(P<0.05)。结论酒石酸美托洛尔联合阿托伐他汀治疗冠心病伴血脂异常的疗效显著。
Objective To observe the clinical efficacy of metoprolol tartrate combined with atorvastatin in treating coronary heart disease with dyslipidemia. Methods 76 cases of coronary heart disease with dyslipidemia were randomly divided into observation group and control group, with 38 cases in each group. Both groups were treated routinely with metoprolol in the control group and metoprolol plus atorvastatin in the observation group for 4 weeks. Results After the treatment, the levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) in the observation group were significantly lower than those before treatment (P0.05), and the levels of high-density lipoprotein cholesterol (P <0.05). The total clinical effective rate in the observation group was 94.74%, which was significantly higher than that in the control group (78.95%, P <0.05). Conclusion Metoprolol tartrate combined with atorvastatin treatment of coronary heart disease with dyslipidemia significant effect.